Abstract 468P
Background
CDK4/6 inhibitors combined with endocrine therapy have revolutionized the treatment of metastatic HR+ breast cancer. However, the influence of low HER2 expression on treatment response and progression-free survival (PFS) remains unclear.
Methods
We conducted a multicenter retrospective study including 204 HR+ breast cancer patients who received a combination of CDK4/6 inhibitor and endocrine therapy. Among them, 138 (68%) patients exhibited HER2-zero disease, while 66 (32%) patients had HER2-low disease. We analyzed treatment-related characteristics and clinical outcomes, with a median follow-up of 22 months.
Results
In the HER2-low group, the objective response rate (ORR) was 72.7%, compared to 66.6% in the HER2-zero group (p=0.54). Median PFS did not significantly differ between the HER2-low and HER2-zero groups (19 months vs. 18 months, p=0.89). Notably, a trend towards longer PFS was observed in the HER2-low group for first-line treatment (24 months progression-free survival rate: 63% vs. 49%). For recurrent disease, the median PFS was 25 months in the HER2-low group and 12 months in the HER2-zero group (p=0.08), while in de novo metastatic disease, the median PFS was 18 months in the HER2-low group and 27 months in the HER2-zero group (p=0.16). Independent variables affecting PFS were identified as the order of CDK4/6 inhibitor use and the presence of visceral metastasis.
Conclusions
Low HER2 expression did not significantly impact treatment response or PFS in HR+ breast cancer patients treated with a CDK4/6 inhibitor and endocrine therapy. Because of the conflicting results in the literature, further prospective studies are needed to evaluate the clinical significance of HER2 expression in HR+ breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1301P - A prognostic clinical and circulating biomarker model to identify futile chemo-radiotherapy (CRT) in stage III NSCLC
Presenter: Rianne Vaes
Session: Poster session 04
1302P - Treatment outcomes and safety of durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in Thai populations: A real-world, multi-center observational study
Presenter: Piyada Sitthideatphaiboon
Session: Poster session 04
1303P - Immune-modulating effects on tumor draining lymph nodes following neoadjuvant chemoradiotherapy combined with immunotherapy in patients with T3-4N0-1 NSCLC
Presenter: Ezgi Ulas
Session: Poster session 04
1304P - A structured multidisciplinary approach for diagnosing immune-related pneumonitis in patients undergoing adjuvant durvalumab for stage III non-small cell lung cancer
Presenter: Illaa Smesseim
Session: Poster session 04
1305P - Importance of the resected lung tumor specimen in patients with locally advanced and metastatic non-small cell lung cancer undergoing prior targeted therapy
Presenter: Jeong Uk Lim
Session: Poster session 04
1307P - The Biocartis Idylla GeneFusion Assay (RUO) for lung cancer testing: The experience of testing over 5000 tumours in routine practice
Presenter: Lee Robertson
Session: Poster session 04
1308P - Diameter threshold for lung nodules at low-dose CT screening: Chinese population screening experience
Presenter: YE WENJUN
Session: Poster session 04
1309P - Immune exhaustion in tumor-free lymph nodes of non-small cell lung cancer (NSCLC) patients is associated with performance status and survival
Presenter: Laura Sellmer
Session: Poster session 04
1310P - Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes
Presenter: Xiwen Liu
Session: Poster session 04
1311P - Understanding the basis for intrinsic resistance to KRASG12C inhibitors
Presenter: Alba Santos Ramos
Session: Poster session 04